Insulet’s aanwezigheid op het ATTD congres bekrachtigt Insulet’s toekomstige toezeggingen aan de diabetesgemeenschap in Europa.
Onderzoeken wijzen op het uitzonderlijk potentieel van het Omnipod Horizon Systeem om de bloedglucosewaardes na specifieke maaltijden en lichamelijke inspanningen stabiel te houden.
BILLERICA, Mass.–(BUSINESS WIRE)– Insulet Corporation (NASDAQ:PODD), de marktleider in infuussetloze insulinepompen met zijn Omnipod® Insuline Management Systeem (Omnipod Systeem), kondigt veelbelovende nieuwe resultaten aan met zijn Omnipod Horizon™ Automated Glucose Control System , een zogeheten hybrid closed-loop systeem. Deze worden op de elfde International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Wenen, Oostenrijk gepresenteerd. Twee studies tonen aan dat het Omnipod Horizon algoritme in 24 volwassenen met type 1 diabetes een uitstekende reactie leverde op maaltijden en lichamelijke inspanningen. Resultaten tonen een solide bloedglucosecontrole binnen het streefbereik aan (70-180 mg/dL of 3.9-10.0 mmol/L) van circa 75% en 85% van de dagdagelijkse uitdagingen met inbegrip van vetrijke maaltijden en matige lichamelijke inspanningen. Er was sprake van een minimale hypoglykemie(<70 mg/dL or <3.9 mmol/L), respectievelijk 0,6% en 1,4% tijdens de 54 uur hybrid closed-loop controle. Aanvullende lange termijn studies zijn aan de gang om het Omnipod Horizon algoritme in vrijlevende omstandigheden te beoordelen in type 1 diabetes patienten van alle leeftijdsgroepen.
Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten met de tekst in de brontaal vergeleken worden, die als enige rechtsgeldig is.
Insulet Has Strong Presence at the International ATTD Congress; Presents Positive Study Results for Its Omnipod Horizon™ Hybrid Closed-Loop System
Studies Show Exceptional Potential for the Omnipod Horizon System to Maintain Stable Blood Glucose Levels after Specific Meal and Exercise Challenges
Significant Presence at ATTD Congress Demonstrates Insulet’s Future Commitment to the Diabetes Community in Europe
BILLERICA, Mass.–(BUSINESS WIRE)– Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced promising new data for its Omnipod Horizon™ Automated Glucose Control System (Omnipod Horizon) hybrid closed-loop system, which will be presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) congress in Vienna, Austria. Two studies demonstrated that the Omnipod Horizon algorithm performed well in response to meal challenges and exercise in 24 adults with type 1 diabetes. Results showed strong blood glucose control with time in target range (70-180 mg/dL or 3.9-10.0 mmol/L) of approximately 75% and 85% with real-life challenges including high-fat meals and moderate intensity exercise. There was minimal hypoglycemia (<70 mg/dL or <3.9 mmol/L), 0.6% and 1.4%, respectively, over 54 hours of hybrid closed-loop control.1,2 Additional longer-term studies are underway to evaluate the Omnipod Horizon algorithm under free-living conditions in patients of all ages with type 1 diabetes.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180214005110/en/
Insulet recently established its European headquarters and will have a booth presence (#15) at the ATTD congress to allow its fast-growing European team to interact directly with the diabetes community attending the meeting. The Company’s presence will highlight Insulet’s global commitment to its customers and its plans for the transition to direct operations on July 1, 2018. Insulet will also hold a satellite symposium, The Omnipod Insulin Management System: Real-World Use and Future Innovation, on Friday, February 16th at 4:40 p.m. local time in Conference Hall M. The Company’s broader presence at ATTD follows the announcement that it is assuming direct distribution, sales, marketing, training and support activities of Insulet’s Omnipod System across Europe beginning July 1, 2018. Latest news about the transition in Europe is available at https://www.omnipodeurope.com.
“We made great progress during 2017 establishing our European operations and building our organization across Europe,” said Shacey Petrovic, President and Chief Operating Officer. “We are deeply focused on continuity of care and delivering the best possible customer experience to Podders in Europe and we are confident our team has the experience and talent to transition this business successfully and bring world-class support and meaningful innovation to our customers across Europe.”
1. Buckingham BA, Christiansen MP, Forlenza GP, et al. Performance of Omnipod Personalized Model Predictive Control Algorithm with Specific Meal Challenges in Adults with Type 1 Diabetes. To be presented at Advanced Technologies & Treatments for Diabetes, February 14-17, 2018.
2. Forlenza GP, Buckingham BA, Christiansen MP, et al. Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise and Variable Setpoints in Adults with Type 1 Diabetes. To be presented at Advanced Technologies & Treatments for Diabetes, February 14-17, 2018.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet’s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.*
*Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it already does in the United States and Canada.
This press release may contain forward-looking statements concerning Insulet’s expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 28, 2017 in the section entitled “Risk Factors,” and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
Investor Relations and Corporate Media Contact:
Deborah R. Gordon, 978-600-7717
Vice President, Investor Relations and Corporate Communications
Dominic Hulton, +44 20 3941 5374
Vice President, Marketing, Europe